- Home
- CON vs FOLD Comparison
CON vs FOLD Comparison
Compare CON & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CON
- FOLD
- Stock Information
- Founded
- CON 1979
- FOLD 2002
- Country
- CON United States
- FOLD United States
- Employees
- CON N/A
- FOLD N/A
- Industry
- CON
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CON
- FOLD Health Care
- Exchange
- CON NYSE
- FOLD Nasdaq
- Market Cap
- CON 2.6B
- FOLD 2.9B
- IPO Year
- CON 2024
- FOLD 2007
- Fundamental
- Price
- CON $20.21
- FOLD $6.13
- Analyst Decision
- CON Strong Buy
- FOLD Strong Buy
- Analyst Count
- CON 7
- FOLD 10
- Target Price
- CON $29.00
- FOLD $26.89
- AVG Volume (30 Days)
- CON 770.7K
- FOLD 3.8M
- Earning Date
- CON 08-07-2025
- FOLD 07-31-2025
- Dividend Yield
- CON 1.23%
- FOLD N/A
- EPS Growth
- CON N/A
- FOLD N/A
- EPS
- CON 1.30
- FOLD N/A
- Revenue
- CON $1,933,346,000.00
- FOLD $543,141,000.00
- Revenue This Year
- CON $13.25
- FOLD $19.87
- Revenue Next Year
- CON $7.48
- FOLD $23.15
- P/E Ratio
- CON $15.58
- FOLD N/A
- Revenue Growth
- CON 4.54
- FOLD 28.25
- 52 Week Low
- CON $18.89
- FOLD $5.51
- 52 Week High
- CON $24.81
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- CON N/A
- FOLD 50.50
- Support Level
- CON N/A
- FOLD $5.97
- Resistance Level
- CON N/A
- FOLD $6.77
- Average True Range (ATR)
- CON 0.00
- FOLD 0.25
- MACD
- CON 0.00
- FOLD 0.01
- Stochastic Oscillator
- CON 0.00
- FOLD 28.09
About CON CONCENTRA GROUP HOLDINGS PARENT INC
Concentra Group Holdings Parent Inc is a provider of occupational health services in the United States. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.